2015
DOI: 10.14227/dt220215p6
|View full text |Cite
|
Sign up to set email alerts
|

Impact of Discordance Among Regulations for Biopharmaceutics Classification System-Based Waivers of Clinical Bioequivalence Studies

Abstract: Approximately 10 years ago, the FDA issued a guidance whereby dissolution could be used to establish bioequivalence for highly soluble and highly permeable immediate-release products. This pathway has advantages in lower costs for pharmaceutical companies and avoids unnecessary exposure of human subjects who would derive no medical benefit from participating in bioequivalence studies. Subsequently, other agencies have also adopted similar guidances. However, there are differences among agency guidances that si… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 9 publications
0
4
0
Order By: Relevance
“…Similar documents were later published by the World Health Organization (WHO) and the European Medicines Agency (EMA). The last one extends the possibility of waiving to class 3 drugs (6).…”
Section: Official Guidelinesmentioning
confidence: 88%
“…Similar documents were later published by the World Health Organization (WHO) and the European Medicines Agency (EMA). The last one extends the possibility of waiving to class 3 drugs (6).…”
Section: Official Guidelinesmentioning
confidence: 88%
“…Sample of the test product is from industrial scale batch (or ≥1/10th of production batch or larger or 100,000 units) which is an additional cost to the generic manufacturer. Considering that an between 555 and 639 BE studies are carried out annually [2] this billions of dollars can be saved by considering the magic word "harmonization". II.…”
Section: The World Health Organization (Who) Has a List Of Prequalifiedmentioning
confidence: 99%
“…Sample of the test product is from industrial scale batch (or ≥1/10 th of production batch or larger or 100,000 units) which is an additional cost to the generic manufacturer. Considering that and between 555 and 639 BE studies are carried out annually [2] this billions of dollars can be saved by considering the magic word "harmonization".…”
Section: Mini Reviewmentioning
confidence: 99%